Skip to Main Content

Paper Details

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.
Nat Commun
5
2023
CD28, CD3, CD4, CD4 and CD8 T cells, CD4-binding site Ab, CD8, CD8 T cells, HIV, HIV infection, HIV-1, N6, SHIV, T cell antigen CD3, T cells, latently-infected cells
Author NameAffiliation
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Krisha McKeeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
John-Paul ToddVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Mark Connors
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
John R MascolaModeX Therapeutics Inc.
  • 1 - 6

Datasets

Release 1.2